BRAF and cancer: Aside from representing distinct cancers, the AML cell lines differ from the A375 melanoma line insofar as both MV4–11 and HL-60 cells are BRAF wildtype, whereas A375 cells possess the BRAF V600E mutation, the oncogenic driver mutation for which Trm most commonly is used clinically.